MAPT and Alzheimer disease: However, we observed a lower NAA/mI ratio, an accepted biomarker of AD [70], in CH-PATs compared to CH-NATs; this, along with the lower CSF Aß42/Tau ratio used to classify the CH-PAT subgroup, provide support that preclinical AD pathology rather than cerebrovascular disease is most likely responsible for the altered executive function.